Currently, there are 7.67M common shares owned by the public and among those 7.37M shares have been available to trade.
However, the script later moved the day high at 3.3900, up 23.15%. The company’s stock has a 5-day price change of 6.38% and 53.37% over the past three months. TRIB shares are trading 16.55% year to date (YTD), with the 12-month market performance down to -30.84% lower. It has a 12-month low price of $1.49 and touched a high of $4.59 over the same period. TRIB has an average intraday trading volume of 120.75K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.43%, -3.44%, and 10.70% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Trinity Biotech Plc ADR (NASDAQ: TRIB) shares accounts for 34.94% of the company’s 7.67M shares outstanding.
It has a market capitalization of $19.10M and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$2.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.96% over the week and 13.77% over the month.
Analysts forecast that Trinity Biotech Plc ADR (TRIB) will achieve an EPS of -0.55 for the current quarter, -0.51 for the next quarter and -1.03 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.55 while analysts give the company a high EPS estimate of -0.55. Comparatively, EPS for the current quarter was -1.32 a year ago. Earnings per share for the fiscal year are expected to increase by 55.57%, and 51.64% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to 9.90% over the past 5-year period.
ROTH Capital was of a view on July 29, 2015 that the stock is Buy, while Roth Capital gave the stock Buy rating on July 22, 2008, issuing a price target of $7- $6. Roth Capital on their part issued Buy rating on March 17, 2008.
